|
AUPQ105799A0
(en)
|
1999-06-18 |
1999-07-08 |
Victor Chang Cardiac Research Institute, The |
Cell growth inhibition
|
|
EP1283053A1
(en)
|
2001-08-09 |
2003-02-12 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Inhibitors of HER3 activity
|
|
EP2400021B1
(en)
*
|
2002-03-26 |
2016-11-30 |
Zensun (Shanghai) Science & Technology, Co., Ltd. |
ErbB3 based methods and compositions for treating neoplasms
|
|
TWI229650B
(en)
*
|
2002-11-19 |
2005-03-21 |
Sharp Kk |
Substrate accommodating tray
|
|
AR056857A1
(es)
*
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
|
JP5656406B2
(ja)
*
|
2006-11-28 |
2015-01-21 |
ユースリー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツングＵ３ Ｐｈａｒｍａ ＧｍｂＨ |
治療効力を予測するためのマーカーとしての活性化ｈｅｒ３
|
|
SG178789A1
(en)
*
|
2007-02-16 |
2012-03-29 |
Merrimack Pharmaceuticals Inc |
Antibodies against erbb3 and uses thereof
|
|
CA2683559C
(en)
|
2007-04-13 |
2019-09-24 |
Dana Farber Cancer Institute, Inc. |
Methods for treating cancer resistant to erbb therapeutics
|
|
PE20090321A1
(es)
*
|
2007-06-04 |
2009-04-20 |
Genentech Inc |
Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
|
|
ES2526211T3
(es)
*
|
2007-07-13 |
2015-01-08 |
Nestec S.A. |
Selección de fármacos para la terapia del cáncer de pulmón utilizando matrices basadas en anticuerpos
|
|
EP2138511A1
(en)
*
|
2008-06-27 |
2009-12-30 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
HER3 as a determinant for the prognosis of melanoma
|
|
UA104868C2
(uk)
*
|
2008-08-15 |
2014-03-25 |
Меррімак Фармасьютікалз, Інк. |
Спосіб лікування пацієнта, що має неопластичну пухлину, відповідно до спрогнозованої реакції
|
|
US8470542B2
(en)
|
2008-12-01 |
2013-06-25 |
Laboratory Corporation Of America Holdings |
Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
|
|
SG172983A1
(en)
|
2009-01-15 |
2011-08-29 |
Lab Corp America Holdings |
Methods of determining patient response by measurement of her-3
|
|
WO2010085845A1
(en)
*
|
2009-01-28 |
2010-08-05 |
The University Of Queensland |
Cancer therapy and/or diagnosis
|
|
CN104447995A
(zh)
*
|
2009-03-20 |
2015-03-25 |
霍夫曼-拉罗奇有限公司 |
双特异性抗-her抗体
|
|
AU2010242914B2
(en)
*
|
2009-04-29 |
2014-11-13 |
Trellis Bioscience, Llc |
Improved antibodies immunoreactive with heregulin-coupled HER3
|
|
MX358013B
(es)
|
2009-11-13 |
2018-08-01 |
Amgen Inc |
Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3.
|
|
MA33892B1
(fr)
*
|
2009-12-22 |
2013-01-02 |
Roche Glycart Ag |
Anticorps anti-her3, et leurs utilisations
|
|
CA2792327C
(en)
|
2010-03-11 |
2019-09-24 |
Merrimack Pharmaceuticals, Inc. |
Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
|
|
CN102884085B
(zh)
|
2010-04-09 |
2016-08-03 |
Aveo制药公司 |
抗erbb3抗体
|
|
EP2590654B1
(en)
|
2010-07-09 |
2016-12-21 |
Exelixis, Inc. |
Combinations of kinase inhibitors for the treatment of cancer
|
|
NZ607337A
(en)
|
2010-08-20 |
2015-06-26 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3)
|
|
TW201302793A
(zh)
*
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
JP6033783B2
(ja)
|
2010-11-01 |
2016-11-30 |
シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ |
Ｐａｎ−ｈｅｒ抗体組成物
|
|
US20140134170A1
(en)
|
2011-03-11 |
2014-05-15 |
Merrimack Pharmaceuticals, Inc. |
Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
|
|
SG192775A1
(en)
|
2011-03-15 |
2013-09-30 |
Merrimack Pharmaceuticals Inc |
Overcoming resistance to erbb pathway inhibitors
|
|
CN105884900A
(zh)
|
2011-04-19 |
2016-08-24 |
梅里麦克制药股份有限公司 |
单特异性和双特异性抗igf-1r和抗erbb3抗体
|
|
NO2707391T3
(https=)
|
2011-05-13 |
2018-04-07 |
|
|
|
KR102101806B1
(ko)
*
|
2011-05-19 |
2020-04-20 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
항-인간-her3 항체 및 이의 용도
|
|
AU2012274461A1
(en)
|
2011-06-20 |
2014-01-16 |
Kyowa Hakko Kirin Co., Ltd. |
Anti-erbB3 antibody
|
|
HK1200468A1
(en)
|
2011-09-30 |
2015-08-07 |
Regeneron Pharmaceuticals, Inc. |
Anti-erbb3 antibodies and uses thereof
|
|
US9273143B2
(en)
|
2011-09-30 |
2016-03-01 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
|
|
US9828635B2
(en)
|
2011-10-06 |
2017-11-28 |
Aveo Pharmaceuticals, Inc. |
Predicting tumor response to anti-ERBB3 antibodies
|
|
AU2012335543C1
(en)
*
|
2011-11-09 |
2017-12-14 |
Beijing Cotimes Biotech Co., Ltd., |
HER3 antibodies and uses thereof
|
|
JP6180425B2
(ja)
*
|
2011-11-23 |
2017-08-23 |
メディミューン，エルエルシー |
Ｈｅｒ３に特異的な結合分子及びそれらの使用
|
|
AU2012349735B2
(en)
|
2011-12-05 |
2016-05-19 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (HER3)
|
|
ES2842201T3
(es)
|
2012-02-23 |
2021-07-13 |
Daiichi Sankyo Europe Gmbh |
Inhibidor de HER3 para modulación de radiosensibilidad
|
|
US9725511B2
(en)
|
2012-11-08 |
2017-08-08 |
Hoffmann-La Roche Inc. |
Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4
|
|
MX2015005757A
(es)
|
2012-11-08 |
2015-11-18 |
Hoffmann La Roche |
Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3.
|
|
CN113201073A
(zh)
|
2012-11-21 |
2021-08-03 |
詹森生物科技公司 |
双特异性EGFR/c-Met抗体
|
|
US9695228B2
(en)
|
2012-11-21 |
2017-07-04 |
Janssen Biotech, Inc. |
EGFR and c-Met fibronectin type III domain binding molecules
|
|
US20170275367A1
(en)
|
2012-11-21 |
2017-09-28 |
Janssen Biotech, Inc. |
Bispecific EGFR/C-Met Antibodies
|
|
US9180185B2
(en)
|
2013-01-11 |
2015-11-10 |
Hoffman-La Roche Inc. |
Combination therapy of anti-HER3 antibodies
|
|
CN105209493B
(zh)
*
|
2013-03-14 |
2019-05-03 |
德克萨斯州大学系统董事会 |
用于诊断和治疗用途的her3特异性单克隆抗体
|
|
WO2014165855A1
(en)
*
|
2013-04-05 |
2014-10-09 |
Laboratory Corporation Of America Holdings |
Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation
|
|
EP2821071A1
(en)
|
2013-07-04 |
2015-01-07 |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Compounds for breast cancer treatment
|
|
US11305012B2
(en)
|
2013-09-24 |
2022-04-19 |
Medimmune, Llc |
Binding molecules specific for HER3 and uses thereof
|
|
CN105899226B
(zh)
|
2013-10-14 |
2020-05-12 |
詹森生物科技公司 |
半胱氨酸工程化iii型纤连蛋白域结合分子
|
|
WO2015066543A1
(en)
*
|
2013-11-01 |
2015-05-07 |
Board Of Regents, The University Of Texas System |
Targeting her2 and her3 with bispecific antibodies in cancerous cells
|
|
EP3087394A2
(en)
|
2013-12-27 |
2016-11-02 |
Merrimack Pharmaceuticals, Inc. |
Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
|
|
KR102399277B1
(ko)
|
2014-04-10 |
2022-05-18 |
다이이찌 산쿄 가부시키가이샤 |
항her3 항체-약물 콘주게이트
|
|
US10745490B2
(en)
|
2014-04-11 |
2020-08-18 |
Celldex Therapeutics, Inc. |
Anti-ErbB antibodies and methods of use thereof
|
|
MX2016014416A
(es)
|
2014-05-14 |
2017-02-23 |
Hoffmann La Roche |
Anticuerpos anti-her3 que se unen a la horquilla beta de her3.
|
|
US10184006B2
(en)
|
2015-06-04 |
2019-01-22 |
Merrimack Pharmaceuticals, Inc. |
Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
|
|
HRP20240338T1
(hr)
|
2015-06-24 |
2024-05-24 |
Janssen Biotech, Inc. |
Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38
|
|
EP4180455A1
(en)
|
2015-06-29 |
2023-05-17 |
Daiichi Sankyo Company, Limited |
Method for selectively manufacturing antibody-drug conjugate
|
|
CR20180177A
(es)
|
2015-09-30 |
2018-06-22 |
Janssen Biotech Inc |
Anticuerpos agonistas que se unen específicamente a cd40 humana y método de uso
|
|
JP2019527540A
(ja)
|
2016-06-21 |
2019-10-03 |
ヤンセン バイオテツク，インコーポレーテツド |
システイン操作フィブロネクチンｉｉｉ型ドメイン結合分子
|
|
BR112019011794A2
(pt)
|
2016-12-12 |
2019-10-29 |
Daiichi Sankyo Co Ltd |
composição farmacêutica, e, método terapêutico.
|
|
NZ754187A
(en)
|
2016-12-14 |
2026-02-27 |
Janssen Biotech Inc |
Cd8a-binding fibronectin type iii domains
|
|
WO2018111976A1
(en)
|
2016-12-14 |
2018-06-21 |
Janssen Biotech, Inc. |
Pd-l1 binding fibronectin type iii domains
|
|
US10611823B2
(en)
|
2016-12-14 |
2020-04-07 |
Hanssen Biotech, Inc |
CD137 binding fibronectin type III domains
|
|
CA3050668C
(en)
|
2017-01-17 |
2023-08-15 |
Daiichi Sankyo Company, Limited |
Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
|
|
JP2020510673A
(ja)
|
2017-03-03 |
2020-04-09 |
ヤンセン バイオテツク，インコーポレーテツド |
がんの治療のための低分子ｃｓｆ−１ｒ阻害剤とｃｄ４０に特異的に結合するアゴニスト抗体とを含む併用療法
|
|
TW202532102A
(zh)
|
2017-05-15 |
2025-08-16 |
日商第一三共股份有限公司 |
抗體－藥物結合物及其用途
|
|
BR112020003466B1
(pt)
|
2017-08-31 |
2023-12-12 |
Daiichi Sankyo Company, Limited |
Métodos de produção de composto, e, composto
|
|
ES3057444T3
(en)
|
2017-08-31 |
2026-03-02 |
Daiichi Sankyo Co Ltd |
Improved method for producing antibody-drug conjugate
|
|
HUE067382T2
(hu)
|
2018-05-18 |
2024-10-28 |
Daiichi Sankyo Co Ltd |
Anti-MUC1-exatecan antitest-hatóanyag konjugátum
|
|
TWI846717B
(zh)
|
2018-07-27 |
2024-07-01 |
日商第一三共股份有限公司 |
辨識抗體-藥物結合物之藥物部位的蛋白質
|
|
TW202537643A
(zh)
|
2018-07-31 |
2025-10-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物之用途
|
|
GB201913079D0
(en)
*
|
2019-09-11 |
2019-10-23 |
Hummingbird Bioscience Holdings Pte Ltd |
Treatment and prevention of cancer using her3 antigen-binding molecules
|
|
WO2021076543A1
(en)
|
2019-10-14 |
2021-04-22 |
Aro Biotherapeutics Company |
Epcam binding fibronectin type iii domains
|
|
WO2021076574A2
(en)
|
2019-10-14 |
2021-04-22 |
Aro Biotherapeutics Company |
Fn3 domain-sirna conjugates and uses thereof
|
|
CN114786682B
(zh)
|
2019-10-14 |
2024-07-16 |
Aro生物疗法公司 |
结合cd71的纤维粘连蛋白iii型结构域
|
|
BR112023021318A2
(pt)
|
2021-04-14 |
2023-12-19 |
Aro Biotherapeutics Company |
Conjugados de domínio fn3-sirna e usos dos mesmos
|
|
CA3214552A1
(en)
|
2021-04-14 |
2022-10-20 |
Russell C. Addis |
Cd71 binding fibronectin type iii domains
|
|
AU2022293634A1
(en)
*
|
2021-06-15 |
2024-01-18 |
Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. |
Anti-her3 antibody, antibody drug conjugate containing the same, and use thereof
|